A new artificial intelligence tool developed by researchers at Cedars-Sinai could transform how doctors select presurgical therapies for breast cancer patients. The tool, named BRIDGE, was detailed in a recent publication in Annals of Oncology alongside early validation data that suggests it can accurately identify genetic subtypes within tumors, moving beyond traditional methods that treat the entire mass as a single category.
According to the press release, BRIDGE reads genetic signals inside a tumor to identify which subtypes are present. This approach could enable more personalized treatment plans, as different subtypes may respond better to specific therapies. For example, some breast cancers are driven by hormone receptors, while others are fueled by HER2 protein or are triple-negative, each requiring distinct approaches.
The development of BRIDGE builds on other advances in cancer research, including work by companies like Calidi Biotherapeutics Inc. (NASDAQ: CLDI), which focuses on developing novel immunotherapies. However, the press release emphasizes that BRIDGE is a diagnostic tool designed to optimize existing treatment protocols rather than a therapeutic agent itself.
Early validation data, as reported in Annals of Oncology, suggests that BRIDGE can successfully parse complex genetic information to differentiate between subtypes that might otherwise be lumped together. This could be particularly valuable for patients with heterogeneous tumors, where different parts of the mass may harbor different genetic drivers. By identifying these nuances, doctors could tailor presurgical treatments—such as chemotherapy, targeted therapy, or hormone therapy—more effectively, potentially improving outcomes and reducing unnecessary side effects.
The implications of this technology extend beyond breast cancer. If validated in larger clinical trials, BRIDGE could serve as a model for AI-driven precision medicine in other cancers and diseases where genetic heterogeneity poses a challenge. The tool represents a step toward integrating artificial intelligence into routine clinical decision-making, offering a data-driven approach to treatment selection that complements traditional pathology.
While the press release includes information about TinyGems, a communications platform that distributed the announcement, the core news is centered on the scientific breakthrough. TinyGems is part of the Dynamic Brand Portfolio @IBN, which provides various media and investor relations services. However, the focus for patients and clinicians remains on the potential of BRIDGE to improve care.
Experts caution that while the early data is promising, further research is needed to confirm the tool’s accuracy and clinical utility. The Cedars-Sinai team plans to conduct larger studies to validate BRIDGE across diverse patient populations and tumor types. If successful, the AI tool could become a standard part of presurgical planning, helping to ensure that each patient receives the most appropriate therapy based on the unique genetic landscape of their cancer.
For more information, the full study is available in Annals of Oncology and additional details can be found on the Cedars-Sinai website. The research highlights the growing role of artificial intelligence in oncology, where machine learning algorithms are increasingly used to analyze complex biomedical data and support clinical decision-making.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is New AI Tool BRIDGE Could Revolutionize Presurgical Treatment Selection for Breast Cancer.